Epidermolysis Bullosa Simplex

A form of epidermolysis bullosa characterized by serous bullae that heal without scarring. Mutations in the genes that encode KERATIN-5 and KERATIN-14 have been associated with several subtypes of epidermolysis bullosa simplex.

Drugs by status

Phase 3 trials (2)

abobotulinumtoxinA
diacerein

Phase 2 trials (5)

apremilast
cannabidiol
rimabotulinumtoxinB
sirolimus
deucravacitinib

Phase 1 trials (2)

jojoba
sulforaphane

Organizations

Organization Involved with Phase 3 Indications (2)

University of Toulouse
University of Nice Sophia Antipolis

Organization Involved with Phase 2 Indications (7)

Stanford University
Premier Specialists, Australia
Tel Aviv University
Uppsala University
Castle Creek Pharmaceuticals
Ichilov Medical Center
University of New South Wales

Organization Involved with Phase 1 Indications (1)

Johns Hopkins University